CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2014—Dako and Merck & Co. will collaborate to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this collaboration will be evaluated as part of the clinical development program from Merck’s investigational anti-PD-1 antibody being studied for the treatment of cancer.
Dako, +45 44 85 95 00